Madison, WI, July 28, 2022 — Elephas Biosciences Corporation (Elephas), a company developing novel cancer diagnostic solutions, announced today the appointment of Steven Galson, M.D., M.P.H., as a member of the Board of Directors.
Dr. Galson is a consultant to Amgen and serves on the Board of Directors of Insilico Medicine and Biocryst Pharmaceuticals. Until June 2020 he was a Senior Vice President of Research and Development at Amgen. He joined the company in 2010 as Vice President of Global Regulatory Affairs.
“I chose to join Elephas because they are developing a platform that will increase access to effective cancer therapies. I am excited to help a team focused on making a positive difference in cancer patients’ lives,” stated Dr. Galson.
Galson spent more than 20 years in government service, including two years as acting Surgeon General of the United States. Previously, he served as Director of the FDA’s Center for Drug Evaluation and Research (CDER), where he provided leadership for the center’s broad national and international programs in pharmaceutical regulation.
“The mission of Elephas is to improve treatment outcomes for cancer patients and provide hope during the difficult battle they face,” said Maneesh Arora, Elephas Founder and CEO. “Adding Dr. Galson’s perspective, driven by his deep knowledge of the pharmaceutical, regulatory, and medical industries, will drive that pursuit forward. We are honored to have him join our board.”
Dr. Galson is the recipient of the Surgeon General’s Medallion and the Secretary of Energy Gold Award. He holds a B.S. from Stony Brook University, an M.D. from Mt. Sinai School of Medicine, and an M.P.H. from the Harvard School of Public Health. Dr. Galson is a Trustee of the Keck Graduate Institute and a founding Governor of the KGI School of Community Medicine. In 2008, he received an Honorary Doctor of Public Service degree from Drexel University School of Public Health. In 2015 he received the Jacobi Medallion Award from Icahn Mount Sinai School of Medicine. In 2018, he was named Health Leader of the Year by the Commissioned Officers Association of the United States Public Health Service. Dr. Galson is on the Executive Committee of the Clinical Trial Transformation Initiative and is a Member of the Forum on Drug Discovery, Development, and Translation at the National Academy of Medicine.
About Elephas
Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers. With the mission to tackle the massive oncology dilemma, Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
Contact
John Fitzpatrick
marketing@elephas.com
